Humacyte (HUMA) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Voyager Therapeutics (VYGR) has outperformed Humacyte (HUMA) over the past year, losing 47.8% versus a loss of 73.5%. Over five years, VYGR leads with a -39.8% price change compared with -95.6% for HUMA. Voyager Therapeutics is the larger company by market cap ($146.0 million vs $124.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUMA | VYGR |
|---|---|---|
| Share price | $0.4471 | $2.37 |
| Market cap | $124.20M | $146.03M |
| 1-day change | -5.34% | -4.05% |
| YTD return | -53.48% | -37.15% |
| 1-year return | -73.54% | -47.78% |
| 5-year return | -95.63% | -39.76% |
| EPS (TTM) | $-0.51 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.90 | $5.55 |
| 52-week low | $0.4367 | $2.33 |
| Distance from 52-week high | -76.41% | -57.30% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +264.57% | +528.27% |
| Average volume | 6.30M | 566.47K |
| Shares outstanding | 277.80M | 61.62M |
| Employees | 184 | 141 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VYGR has outperformed HUMA by 25.8 percentage points over the past year.
- The two companies sit in different sectors: Humacyte in Healthcare and Voyager Therapeutics in Health Care.
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Healthcare · Biotechnology · 184 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
HUMA vs VYGR FAQ
Which is bigger, Humacyte or Voyager Therapeutics?
Voyager Therapeutics (VYGR) is larger, with a market capitalization of $146.03M compared with $124.20M for Humacyte (HUMA).
Which stock has performed better over the past year, HUMA or VYGR?
VYGR returned -47.78% over the past 12 months, compared with -73.54% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Humacyte and Voyager Therapeutics in the same industry?
No. Humacyte is in the Healthcare sector, while Voyager Therapeutics is in Health Care.